我公司致力于為客戶提供高純度、低成本的活性重組蛋白，包括重組人VEGFR2在內的各類受體、細胞因子、生長因子、轉錄因子、激素、酶、毒性蛋白、病毒抗原等。...

特別提示：包括重組人VEGFR2(KDR)(血管內皮生長因子受體2)在內，本公司的所有產品僅可用于科研實驗，嚴禁用于臨床醫療及其他非科研用途！

產品名稱：重組人VEGFR2(KDR)(血管內皮生長因子受體2)
英文名稱：Recombinant Human Vascular Endothelial Growth Factor Receptor 2
產品貨號：JN1379
產品規格：10μg|50μg|500μg|1mg

本品由我們的哺乳動物細胞表達系統制備而成，目的基因編碼的Ala20-Glu764在C端帶有Fc標簽。

VEGFR2/KDR質量控制：＞95%(還原性SDS-PAGE)

VEGFR2/KDR制劑：凍干品

VEGFR2/KDR保存：
凍干蛋白置于-20℃以下可長期保存，室溫條件下可穩定保存3周。
復溶蛋白溶液可在4～7℃保存2～7天，可分裝后置于-20℃保存三個月。

VEGFR2/KDR復溶：
打開試劑管前請先離心。
復溶濃度推薦大于100 μg/ml。
凍干蛋白請溶于ddH2O。
復溶后，請根據用量分裝凍存，避免反復凍融。

關于VEGFR2/KDR：
Human Vascular endothelial growth factor receptor 2(KDR, VEGFR-2) is a member of the class III subfamily of receptor tyrosine kinases (RTKs). KDR is involved in a number of fundamental biological processes such as the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. It also plays an essential role in promoting proliferation, survival, migration and differentiation of endothelial cells, reorganization of the actin cytoskeleton. VEGFR2 is identified as the receptor for VEGF and VEGFC and an early marker for endothelial cell progenitors, whose expression is restricted to endothelial cells in vivo.The adaptor protein SHB has been shown to interact with VEGFR2 in receptor tyrosine kinase signaling. In addition, VEGFR2 is able to interact with HIV-1 extracellular Tat protein upon VEGF activation, and seems to enhance angiogenesis in Kaposis sarcoma lesions. VEGF R2 is thought to be the primary inducer of VEGF-mediated blood vessel growth, while VEGF R3 plays a significant role in VEGF-C and VEGF-D-mediated lymphangiogenesis.

根據您的關注的重組人VEGFR2(KDR)(血管內皮生長因子受體2)，重組VEGFR2，rhVEGFR2，重組人血管內皮生長因子受體2，重組血管內皮生長因子受體2，重組Vascular Endothelial Growth Factor Receptor 2，重組人Vascular Endothelial Growth Factor Receptor 2，rKDR，rhKDR，重組KDR，Recombinant Human Vascular Endothelial Growth Factor Receptor 2，rVEGFR2，重組人KDR，重組人VEGFR2，您可能還對以下產品有需求：

貨號	名稱	規格
JN0490	重組人OX40(TNFRSF4)(CD134)(C端His標簽)	10μg|50μg|500μg|1mg
JN2033	重組人UDP-葡萄糖-4-差向異構酶	10μg|50μg|500μg|1mg
JN0770	重組人SHMT1(胞質絲氨酸羥甲基轉移酶)	10μg|50μg|500μg|1mg
JN0897	重組人對羥苯基丙酮酸雙氧化酶(4HPPD)	10μg|50μg|500μg|1mg
JN0950	重組人蛋白精氨酸甲基轉移酶1(PRMT1)	10μg|50μg|500μg|1mg
JN1301	重組人膠質細胞源性神經營養因受體α2(GFRA2)	10μg|50μg|500μg|1mg

關注重組人VEGFR2(KDR)(血管內皮生長因子受體2)，重組VEGFR2，rhVEGFR2，重組人血管內皮生長因子受體2，重組血管內皮生長因子受體2，重組Vascular Endothelial Growth Factor Receptor 2，重組人Vascular Endothelial Growth Factor Receptor 2，rKDR，rhKDR，重組KDR，Recombinant Human Vascular Endothelial Growth Factor Receptor 2，rVEGFR2，重組人KDR，重組人VEGFR2的同時，為您推薦更多您可能感興趣的產品：



名稱：重組大鼠血管內皮生長因子A(VEGF-A)(VEGF164)
貨號：JN0269
規格：10μg|50μg|500μg|1mg
本品由我們的酵母表達系統制備，目的基因編碼的Ala27-Arg190表達純化而來。

VEGF164質量控制：＞95%(還原性SDS-PAGE)。

VEGF164制劑：凍干品

VEGF164保存：
凍干蛋白可在-20℃長期保存，室溫也可穩定保存3周。
復溶蛋白溶液可在4～7℃保存2～7天。
復溶后建議分裝凍存在-20℃，可保存3個月，應避免反復凍融。

VEGF164復溶：
1、試劑開蓋前請先離心。
2、復溶濃度應大于100 μg/ml.
3、凍干蛋白溶于ddH2O中
4、復溶后根據使用量分裝保存，避免反復凍融。

關于VEGF164：
Vascular endothelial growth factor (VEGF/VEGF-A ) is originally known as vascular permeability factor (VPF). It belongs to the PDGF family with a cysteine-knot structure comprised of eight conserved cysteine residues, and reckoned as a potent mediator in the process of angiogenesis and vasculogenesis in either fetus or adult. VEGF is particularly expressed in supraoptic , paraventricular nuclei and the choroid plexus of the pituitary, and abundant in the corpus luteum of the ovary and in kidney glomeruli. The rat VEGF protein contains a putative 20 amino acids (aa) signal peptide, and alternative splicing of rat VEGF gene produces isoforms of 120, 144, 164 and 188 aa. Rat VEGF164 respectively displays 97% and 88% aa identity with that regions of mouse and human VEGF. VEGF can bind to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin, and play important roles in inducing endothelial cell proliferation, promoting cell migration, inhibiting apoptosis and inducing permeabilization of blood vessels.

如果您覺得“JN1379 重組人VEGFR2”描述資料不夠齊全，請聯系我們獲取詳細資料。(聯系時請告訴我從給覽網看到的，我們將給您最大優惠！)
本頁鏈接：http://www.lgsztm.com/com_bjbiolab01/sell/itemid-8543944.html
已經有850位訪客查看了本頁.